Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER Positive, HER2 Negative Breast Cancer Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05101564
What this trial is testing

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Jennifer Lee Caswell-Jin 19
Large-scale testing (Phase 3)Study completedNCT03096847
What this trial is testing

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 502
Early research (Phase 1)Study completedNCT02684032
What this trial is testing

Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Celcuity Inc 141
Testing effectiveness (Phase 2)Active Not RecruitingNCT04443348
What this trial is testing

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Who this might be right for
Triple Negative Breast CancerHormone Receptor Positive (HR+), HER2-negative Breast CancerBiopsy-proven, Positive Lymph Node(s)
Laura M. Spring, MD 120
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Testing effectiveness (Phase 2)Study completedNCT03633331
What this trial is testing

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7
Alliance for Clinical Trials in Oncology 93
Testing effectiveness (Phase 2)Study completedNCT03691493
What this trial is testing

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+4 more
Emory University 36
Testing effectiveness (Phase 2)Study completedNCT05150652
What this trial is testing

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerNode-negative Breast Cancer+1 more
Irada Ibrahim-zada 8
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Testing effectiveness (Phase 2)Active Not RecruitingNCT05069038
What this trial is testing

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Who this might be right for
Breast Cancer
University of Nebraska 51
Early research (Phase 1)Active Not RecruitingNCT05293964
What this trial is testing

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 214
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Post-approval studies (Phase 4)Active Not RecruitingNCT05486182
What this trial is testing

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 153
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Large-scale testing (Phase 3)Looking for participantsNCT06492616
What this trial is testing

Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 4,220
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Large-scale testing (Phase 3)Active Not RecruitingNCT01953588
What this trial is testing

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast Carcinoma+6 more
Alliance for Clinical Trials in Oncology 1,473
Large-scale testing (Phase 3)Not Yet RecruitingNCT07827573
What this trial is testing

Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Who this might be right for
Early Breast CancerEstrogen Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Hoffmann-La Roche 1,500
Testing effectiveness (Phase 2)Ended earlyNCT02236572
What this trial is testing

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Who this might be right for
Breast Cancer
Yale University 17
Testing effectiveness (Phase 2)WithdrawnNCT03841747
What this trial is testing

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Queen Mary University of London
Next Page